Baltimore digital health company WellDoc plans to push its flagship diabetes management tool nationally and globally following a $22 million financing round.
The Series B round, led by Samsung Ventures with returning investor Merck Global Health Innovation Fund, will give WellDoc the cash and connections needed to scale up its U.S. Food and Drug Administration-approved program for adults with type 2 diabetes, called BlueStar.
{iframe}http://www.bizjournals.com/baltimore/blog/cyberbizblog/2015/12/welldoc-to-make-national-and-international-push.html?ana=e_du_pub&s=article_du&ed=2015-12-17&u=wjGEy67ABoSnsLErlc5ry0j5hx3&t=1450704283{/iframe}